9.57

2.35% -0.23

After Hours: 9.96 0.39 +4.08%

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $9.57, with a volume of 706.89K. It is down -2.35% in the last 24 hours and down -8.16% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Previous Close:

$9.80

Open:

$9.9

24h Volume:

706.89K

Relative Volume:

0.35

Market Cap:

$1.32B

Revenue:

$62.04M

Net Income/Loss:

$-533.34M

P/E Ratio:

-2.4413

EPS:

-3.92

Net Cash Flow:

$-473.07M

1W Performance:

-0.83%

1M Performance:

-8.16%

6M Performance:

+10.38%

1Y Performance:

-5.34%

1-Day Range:

$9.51

$9.93

1-Week Range:

$9.51

$9.98

52-Week Range:

$6.56

$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

587

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	9.57	1.32B	62.04M	-533.34M	-473.07M	-3.92
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

Feb 20, 2025

(VIR) Trading Advice - Stock Traders Daily

Feb 20, 2025

Feb 19, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - BioSpace

Feb 19, 2025

Vir Biotechnology director George Scangos sells $107,575 in stock By Investing.com - Investing.com South Africa

Feb 19, 2025

Vir Biotechnology director George Scangos sells $107,575 in stock - Investing.com

Feb 19, 2025

Will Vir Biotechnology Reveal New Strategic Initiatives? Key Conference Appearance Ahead - StockTitan

Feb 19, 2025

Feb 18, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Empowered Funds LLC - MarketBeat

Feb 18, 2025

Feb 17, 2025

Brent Sabatini Sells 1,562 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock - MarketBeat

Feb 17, 2025

Feb 16, 2025

Vir Biotechnology SVP sells shares for $14,291 - MSN

Feb 16, 2025

Xencor, Inc. Enters License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat Covid-19 with Vir Biotechnology - Marketscreener.com

Feb 16, 2025

Feb 15, 2025

Vir Biotechnology (NASDAQ:VIR) Shares Down 4.8%Here's Why - MarketBeat

Feb 15, 2025

Feb 14, 2025

Vir Biotechnology SVP sells shares for $14,291 By Investing.com - Investing.com Nigeria

Feb 14, 2025

Vir Biotechnology Officer Sells Shares to Cover Tax Obligations - TradingView

Feb 14, 2025

Feb 12, 2025

abrdn plc Buys Shares of 363,161 Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Feb 12, 2025

Vir Biotechnology Sets Stage for Major Corporate Strategy Reveal with Q4 Earnings - StockTitan

Feb 12, 2025

Feb 10, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Feb 10, 2025

Feb 09, 2025

After a year of 7.8% returns, Vir Biotechnology, Inc.'s (NASDAQ:VIR) share price drop last week may have less of an impact on institutional investors - Simply Wall St

Feb 05, 2025

Feb 04, 2025

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer - BioSpace

Feb 04, 2025

Feb 03, 2025

HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Feb 03, 2025

Feb 02, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Update - MarketBeat

Feb 02, 2025

Jan 31, 2025

Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Australia

Jan 31, 2025

Jan 30, 2025